The objective response rates obtained for either sotorasib or adagrasib is markedly lower compared to those obtained with osimertinib or alectinib in EGFR and ALK-driven NSCLC respectively (95, 96), suggesting the presence of intrinsic mechanisms of resistance to KRAS G12C inhibitors. This evidence concerns the gene KRAS and non-small cell lung carcinoma.